Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health reform office prescribed for HHS

This article was originally published in The Tan Sheet

Executive Summary

President Obama orders the creation of the Office of Health Reform within the Department of Health and Human Services to coordinate with its counterpart office in the White House in developing and carrying out the president's health reform goals. The April 8 executive order adds that the health reform office will engage in public outreach, work with Congress and agencies to eliminate health care barriers and gather input on policy measures to meet the president's health care goals. Obama's health reform advisor, Nancy-Ann DeParle, leads the White House office, and congressional staffers say health policy expert Jeanne Lambrew will head the HHS office. Lambrew was slated to serve as Tom Daschle's deputy in the White House health reform office and has served at HHS since Daschle's withdrawal as HHS secretary-designate (1"The Tan Sheet" Feb. 23, 2009, p. 12)

You may also be interested in...

Lambrew’s Departure Would Leave Clean Slate For Incoming Health Czar

The expected departure of White House Office of Health Care Reform Deputy Director Jeanne Lambrew allows the next Health and Human Services secretary complete flexibility to bring in key health policy personnel as the Obama administration readies for an intense health reform debate in the coming months

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts